Cargando…

Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review

This review focuses on the evidence for neurotherapeutics for attention deficit/hyperactivity disorder (ADHD). EEG-neurofeedback has been tested for about 45 years, with the latest meta-analyses of randomised controlled trials (RCT) showing small/medium effects compared to non-active controls only....

Descripción completa

Detalles Bibliográficos
Autores principales: Rubia, Katya, Westwood, Samuel, Aggensteiner, Pascal-M., Brandeis, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394071/
https://www.ncbi.nlm.nih.gov/pubmed/34440925
http://dx.doi.org/10.3390/cells10082156
_version_ 1783743864800018432
author Rubia, Katya
Westwood, Samuel
Aggensteiner, Pascal-M.
Brandeis, Daniel
author_facet Rubia, Katya
Westwood, Samuel
Aggensteiner, Pascal-M.
Brandeis, Daniel
author_sort Rubia, Katya
collection PubMed
description This review focuses on the evidence for neurotherapeutics for attention deficit/hyperactivity disorder (ADHD). EEG-neurofeedback has been tested for about 45 years, with the latest meta-analyses of randomised controlled trials (RCT) showing small/medium effects compared to non-active controls only. Three small studies piloted neurofeedback of frontal activations in ADHD using functional magnetic resonance imaging or near-infrared spectroscopy, finding no superior effects over control conditions. Brain stimulation has been applied to ADHD using mostly repetitive transcranial magnetic and direct current stimulation (rTMS/tDCS). rTMS has shown mostly negative findings on improving cognition or symptoms. Meta-analyses of tDCS studies targeting mostly the dorsolateral prefrontal cortex show small effects on cognitive improvements with only two out of three studies showing clinical improvements. Trigeminal nerve stimulation has been shown to improve ADHD symptoms with medium effect in one RCT. Modern neurotherapeutics are attractive due to their relative safety and potential neuroplastic effects. However, they need to be thoroughly tested for clinical and cognitive efficacy across settings and beyond core symptoms and for their potential for individualised treatment.
format Online
Article
Text
id pubmed-8394071
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83940712021-08-28 Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review Rubia, Katya Westwood, Samuel Aggensteiner, Pascal-M. Brandeis, Daniel Cells Review This review focuses on the evidence for neurotherapeutics for attention deficit/hyperactivity disorder (ADHD). EEG-neurofeedback has been tested for about 45 years, with the latest meta-analyses of randomised controlled trials (RCT) showing small/medium effects compared to non-active controls only. Three small studies piloted neurofeedback of frontal activations in ADHD using functional magnetic resonance imaging or near-infrared spectroscopy, finding no superior effects over control conditions. Brain stimulation has been applied to ADHD using mostly repetitive transcranial magnetic and direct current stimulation (rTMS/tDCS). rTMS has shown mostly negative findings on improving cognition or symptoms. Meta-analyses of tDCS studies targeting mostly the dorsolateral prefrontal cortex show small effects on cognitive improvements with only two out of three studies showing clinical improvements. Trigeminal nerve stimulation has been shown to improve ADHD symptoms with medium effect in one RCT. Modern neurotherapeutics are attractive due to their relative safety and potential neuroplastic effects. However, they need to be thoroughly tested for clinical and cognitive efficacy across settings and beyond core symptoms and for their potential for individualised treatment. MDPI 2021-08-21 /pmc/articles/PMC8394071/ /pubmed/34440925 http://dx.doi.org/10.3390/cells10082156 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rubia, Katya
Westwood, Samuel
Aggensteiner, Pascal-M.
Brandeis, Daniel
Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review
title Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review
title_full Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review
title_fullStr Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review
title_full_unstemmed Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review
title_short Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review
title_sort neurotherapeutics for attention deficit/hyperactivity disorder (adhd): a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394071/
https://www.ncbi.nlm.nih.gov/pubmed/34440925
http://dx.doi.org/10.3390/cells10082156
work_keys_str_mv AT rubiakatya neurotherapeuticsforattentiondeficithyperactivitydisorderadhdareview
AT westwoodsamuel neurotherapeuticsforattentiondeficithyperactivitydisorderadhdareview
AT aggensteinerpascalm neurotherapeuticsforattentiondeficithyperactivitydisorderadhdareview
AT brandeisdaniel neurotherapeuticsforattentiondeficithyperactivitydisorderadhdareview